SecBot SecBot
8-K ·Filed Nov 10, 2026

MIRM

Mirum Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed6d 17h ago SEC0001759425-26-000064
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor for BLA submission in H1 2027 and FDA acceptance/priority review. The AZURE-1 and AZURE-4 data package will be key for regulatory approval; any safety or efficacy concerns in the full dataset could affect the timeline. Also watch for potential partnership or commercialization updates.

DirectionBullish
Confidencehigh
Horizonmonths

brelovitug

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3 (completed)
Time to market
Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
Next catalyst
BLA filing · H1 2027

What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$94.42
T+0 close · Nov 10, 2026 · via day close
Latest settled
+0.20%
T+1 · $94.61
Vs SPY
−1.12%
α at T+1
Next horizon
T+5
in 6h
  1. T+0 · Nov 10 $94.42entry
  2. T+1 · 6d ago +0.20%α −1.12% · $94.61
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum announced that its Phase 3 AZURE-4 study for brelovitug in chronic hepatitis delta virus (HDV) met the primary endpoint at Week 24, with 59% (300 mg QW) and 44% (900 mg Q4W) of patients achieving virologic response and ALT normalization versus 0% in the delayed-treatment arm (p<0.0001). This is the second positive Phase 3 study for brelovitug, supporting a planned BLA submission in H1 2027 with a potential U.S. launch in Q4 2027. The data also showed deepening viral suppression and ALT normalization with longer treatment, including in patients with advanced cirrhosis.

Key Facts

  • AZURE-4 Phase 3 study met primary endpoint at Week 24: 59% (300 mg QW) and 44% (900 mg Q4W) achieved combined virologic response and ALT normalization vs 0% in delayed-treatment arm (p<0.0001 for both)
  • AZURE-4 is the second of two Phase 3 studies forming the U.S. registration package for brelovitug
  • Company plans to submit BLA to FDA in first half of 2027, with potential U.S. commercial launch in Q4 2027 if approved
  • Long-term data (up to 108 weeks) showed deepening viral suppression, increased ALT normalization, and improvements in liver stiffness
  • No new safety signals; most common adverse event was flu-like illness (17.2%-18.5%), low injection site reactions (1.7%-7.4%)
  • Study enrolled 113 treatment-naive patients, 53% with cirrhosis, mean baseline ALT 122 U/L

Financial Impact

No financial figures disclosed; brelovitug is an investigational asset with no approved revenue. Positive Phase 3 data supports regulatory filing and potential future revenue from HDV treatment.

revenueregulatory approval probability

Risk Factors

  • BLA submission and FDA approval are not guaranteed; regulatory review may require additional data or raise safety/efficacy questions
  • Commercial launch is contingent on approval and market acceptance; HDV is a niche indication with limited patient population
  • Competing therapies in development for HDV could affect market share if brelovitug is approved

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759425-26-000064
Document: 0001759425-26-000064-index-headers.html0001759425-26-000064
Document: 0001759425-26-000064-index.html0001759425-26-000064
Document: 0001759425-26-000064.txt0001759425-26-000064

Track record

27 reports on MIRM

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
  4. Nov 10, 20266d ago 8-K Bullish 6/10 Viewing Entry $94.42 Now $91.58 −3.01% settles Feb 8
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  7. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
  9. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
  10. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
Showing 10 of 27

US Market Status

Market Closed · Opens in 8h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026